Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
1. A method of treating pancreatic cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound that is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
2. A method according to claim 1 , wherein said compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof.
3. A method according to claim 2 , further comprising administering to said patient an additional therapeutic agent.
4. The method according to claim 3 , wherein said additional therapeutic agent is a chemotherapeutic agent.
5. The method according to claim 4 , wherein said method comprises administering said compound, or said salt, and said chemotherapeutic agent simultaneously to the patient.
6. The method according to claim 4 , wherein said method comprises administering said compound, or said salt, and said chemotherapeutic agent sequentially to said patient.
7. The method according to claim 2 , wherein about 5 to about 1000 mg of said compound or said salt is administered to said patient.